drugset / Trial / NCT01442259

An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects

NCT01442259

Phase 1 Completed 48 enrolled Novartis Pharmaceuticals
NaParallel-groupOpen-labelOther

Summary

The aim of this study was to characterize the pharmacokinetics and safety of AFQ056 in subjects with a different degree of renal impairment.

Timeline

Start
2011-01
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Mavoglurant Small molecule

Indications

No indication recorded.